-

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences:

  • TD Cowen 46th Annual Health Care Conference, March 4, 2026
  • KeyBanc Capital Markets Healthcare Forum, March 17, 2026
  • Bloom Burton & Co. Healthcare Investor Conference, April 21-22, 2026

A live audio webcast of each presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website closer to date. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology. For more information, please visit www.abcellera.com.

Contacts

Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Industry:

AbCellera Biologics Inc.

NASDAQ:ABCL
Release Summary
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
Release Versions
English
$Cashtags
$ABCL

Contacts

Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Social Media Profiles
AbCellera on LinkedIn
AbCellera on Twitter
More News From AbCellera Biologics Inc.

AbCellera Reports Full Year 2025 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Reports Full Year 2025 Business Results...

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera to Report Full Year 2025 Financial Results on February 24, 2026...

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause...
Back to Newsroom